<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339701</url>
  </required_header>
  <id_info>
    <org_study_id>PST005</org_study_id>
    <nct_id>NCT02339701</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer</brief_title>
  <official_title>A Randomized, Open Label, Phase II Study: Stereotactic Body Radiotherapy (SBRT) vs Conventional Intensity-modulated Radiotherapy (IMRT) for Low or Intermediate Risk Prostate Cancer in Asia Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this phase II study is to compare the change of EPIC HRQOL scores (1-year&#xD;
      minus baseline) between SBRT and IMRT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>health-related quality of life (HRQOL)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of acute and late GI and GU toxicity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical-failure free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-specific survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <arm_group_label>IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of prostate adenocarcinoma&#xD;
&#xD;
          -  Low or intermediate risk prostate cancer patients (i.e. T1-T2c and PSA 20 and Gleason&#xD;
             score &lt; 8) with the risk of pelvic node metastasis 15% as calculated by Roach's&#xD;
             formula&#xD;
&#xD;
          -  ECOG performance score 0-1&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  History/physical examination within 2 weeks prior to registration&#xD;
&#xD;
          -  Able to sign informed-consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous diagnosis of cancer other than prostate cancer and non-melanoma&#xD;
             skin cancer.&#xD;
&#xD;
          -  Evidence of distant metastases&#xD;
&#xD;
          -  Regional lymph node involvement&#xD;
&#xD;
          -  Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer&#xD;
&#xD;
          -  Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy&#xD;
&#xD;
          -  Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or&#xD;
             LHRHantagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide),&#xD;
             estrogens (e.g.DES), or surgical castration (orchiectomy)&#xD;
&#xD;
          -  Unstable angina and/or congestive heart failure requiring hospitalization, transmural&#xD;
             myocardial infarction within the last 6 months, acute bacterial or fungal infection&#xD;
             requiring intravenous antibiotics, chronic obstructive pulmonary disease exacerbation&#xD;
             or other respiratory illness requiringhospitalization or precluding study therapy at&#xD;
             the time of registration&#xD;
&#xD;
          -  Patients who have received prior chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darren MC POON, FHKCR</last_name>
    <phone>3505 2128</phone>
    <email>mc_poon@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Candy Yuen, RN</last_name>
    <phone>3505 1040</phone>
    <email>sf_yuen@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren MC POON, FHKCR</last_name>
      <phone>3505 2128</phone>
      <email>mc_poon@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Candy Yuen, RN</last_name>
      <phone>3505 1040</phone>
      <email>sf_yuen@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

